HDAC9 and melanoma: In summary, we have shown, using clinically relevant human pre-clinical models of innate and adaptive anti-tumor immune priming, that HSVGM-CSF is capable of activating an anti-melanoma immune response and that the cytotoxicity and immunogenicity of the currently most clinically advanced class of OV is further boosted by combination with HDAC inhibition.